TWST
Twist Bioscience CorporationNASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
6.85
P/S
8.01
EV/EBITDA
-62.02
DCF Value
$-63.61
FCF Yield
-2.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
51.6%
Operating Margin
-34.4%
Net Margin
-19.6%
ROE
-16.6%
ROA
-12.0%
ROIC
-23.6%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $103.7M | $-30.5M | $-0.50 |
| Q4 2025 | $99.0M | $-27.1M | $-0.45 |
| FY 2025 | $376.6M | $-77.7M | $-1.30 |
| Q3 2025 | $96.1M | $20.4M | $0.33 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
2.21
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has collaboration agreements with Victorian Clinical Genetic Services; Vivlion GmbH.; Kyowa Kirin Pharmaceutical Research, Inc.; deepCDR Biologics AG; and Centogene N.V to develop advanced sequencing tools. It also has a research collaboration with Boehringer Ingelheim International GmbH to use proprietary antibody libraries to discover therapeutic antibodies against multiple targets. Twist Bioscience Corporation was incorporated in 2013 and is headquartered in South San Francisco, California.